Genetic Engineering & Biotechnology NewsIt’s been no secret that screening methods to detect prostate cancer have been woefully lacking and largely inconsistent with respect to the results they provide. Yet, with the rise in validated biomarkers and advanced diagnostics coupled with next Prostate cancer blood test ‘helps target treatment’ ..
STAMPEDE: Abiraterone Slowed Progression of Advanced Prostate Cancer
Cancer NetworkCHICAGO—Adding abiraterone at the start of androgen deprivation therapy (ADT) for men with high-risk locally advanced or metastatic prostate cancer significantly improved overall survival and failure-free survival, with a manageable toxicity profile, …Prostate cancer treatment ‘could help more patients’ ..
Early Intervention With Abiraterone Significantly Reduces Risk in Metastatic Prostate Cancer, Results of 2 Studies Show
Targeted OncologyIn findings from 2 clinicals, abiraterone acetate (Zytiga) was found to lower the risk of death by almost 40% in men with newly diagnosed high-risk advanced or metastatic prostate cancer, or in men who had not yet received hormone therapy for their Abiraterone: Now Upfront for Advanced Prostate Cancer? ..
MSKCC Researchers Debut High-Intensity Liquid Biopsy Method Developed With Grail
The GuardianCHICAGO (GenomeWeb) – At this week’s annual meeting of the American Society of Clinical Oncology, researchers from Memorial Sloan Kettering Cancer Center shared new data on a method that they highlighted as a first step toward a test that can detect …New technology dives deep into the cancer genome ..
Drug Extends Lives of Patients With Advanced Prostate Cancer: Studies
HealthDaySATURDAY, June 3, 2017 (HealthDay News) — Men with advanced prostate cancer might be able to avoid chemotherapy by taking an additional anti-testosterone pill along with standard hormone therapy, a pair of new clinical trials show. The drug …Early use of J&J’s Zytiga extends prostate cancer survival ..
Prostate cancer treatment ‘could help more patients’
BBC NewsOne of the largest clinical trials for prostate cancer has given “powerful results”, say UK researchers. A drug for treating prostate cancer that has spread was found to save lives when offered earlier, a study found. The trial looked at abiraterone as J&J’s Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients ..
Abiraterone: Now Upfront for Advanced Prostate Cancer?
MedscapeCHICAGO — New results with first-line use of abiraterone (Zytiga, Janssen) are set to transform the upfront treatment of advanced prostate cancer “practically overnight,” based on results of the STAMPEDE and LATITUDE trials presented here at the Drug Extends Lives of Patients With Advanced Prostate Cancer: Studies ..
Early use of J&J’s Zytiga extends prostate cancer survival
BBC NewsCHICAGO Adding Johnson & Johnson’s Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.Prostate cancer treatment ‘could help more patients’ ..
Abiraterone/ADT Combo Increased Prostate Cancer Survival
Cancer NetworkCombined therapy with abiraterone acetate/prednisone plus androgen deprivation therapy (ADT) significantly improved overall survival and radiographic progression-free survival (PFS) among men with metastatic hormone-naive prostate cancer compared …Early use of J&J’s Zytiga extends prostate cancer survival ..